menu
    • menu

    Company profile for Halia Therapeutics

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Halia Therapeutics we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.We use an innovative approach to drug discovery by translating advances in the ...
    At Halia Therapeutics we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.We use an innovative approach to drug discovery by translating advances in the understanding of the importance of inflammation in human pathologies such as cancer and neurodegenerative diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Halia TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1865 W 2100 S, Suite 100 Salt Lake City, Utah 84119
    Telephone
    Telephone
    (385) 355-4315
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.haliatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/halia-therapeutics-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Halia Therapeutics Reports Ofirnoflast Success In Lower-Risk MDS
    Halia Therapeutics Reports Ofirnoflast Success In Lower-Risk MDS

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-announces-positive-phase-2a-data-for-ofirnoflast-in-lower-risk-mds-at-ash-2025-302635415.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Halia Therapeutics Unveils Novel NEK7 Inhibitor Data At ASH 2025
    Halia Therapeutics Unveils Novel NEK7 Inhibitor Data At ASH 2025

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-to-present-groundbreaking-data-on-novel-allosteric-nek7-inhibitor-ofirnoflast-at-the-2025-american-society-of-hematology-annual-meeting-302609730.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Ofirnoflast Gets Orphan Drug Tag for Myelodysplastic Syndromes
    Ofirnoflast Gets Orphan Drug Tag for Myelodysplastic Syndromes

    23 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-us-fda-for-myelodysplastic-syndromes-302592239.html

    PR NEWSWIRE
    23 Oct 2025
    Share Share
    Halia Therapeutics Appoints Paul Jones As Chief Strategy Officer
    Halia Therapeutics Appoints Paul Jones As Chief Strategy Officer

    06 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-strengthens-global-genomics-leadership-with-appointment-of-paul-jones-as-chief-strategy-officer--gm-international-markets-302575149.html

    PR NEWSWIRE
    06 Oct 2025
    Share Share
    Halia Therapeutics Joins Morgan Stanley Global Healthcare Conf
    Halia Therapeutics Joins Morgan Stanley Global Healthcare Conf

    04 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference-302546054.html

    PR NEWSWIRE
    04 Sep 2025
    Share Share
    Halia Completes Ph1 Study of HT-4253 for Neuroinflammation
    Halia Completes Ph1 Study of HT-4253 for Neuroinflammation

    16 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253-a-novel-lrrk2-inhibitor-targeting-neuroinflammation-302482102.html

    PR NEWSWIRE
    16 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search